Home LiteratureArticle Details
PMID: 16447113 Published · ppublish English Comment Editorial Research Support, N.I.H., Extramural

Injection drug users: the overlooked core of the hepatitis C epidemic.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America ·Vol. 42 ·No. 5 ·2006-03-01 ·Pages 673-6

Edlin BR, Carden MR

Abstract

暂无摘要

MeSH Terms
Disease Outbreaks Hepatitis C/epidemiology Humans Substance Abuse, Intravenous
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Edlin Brian R
Carden Michael R
References (45)
45 references, click to expand
  1. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study.
    Am J Gastroenterol. 2004 Apr;99(4):636-44 PMID: 15089895
  2. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.
    Hepatology. 2000 Mar;31(3):777-82 PMID: 10706572
  3. Analysis of successful immune responses in persons infected with hepatitis C virus.
    J Exp Med. 2000 May 1;191(9):1499-512 PMID: 10790425
  4. Liver transplantation and opioid dependence.
    JAMA. 2001 Feb 28;285(8):1056-8 PMID: 11209177
  5. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.
    Am J Public Health. 2001 Jan;91(1):46-7 PMID: 11189823
  6. Sharing of drug preparation equipment as a risk factor for hepatitis C.
    Am J Public Health. 2001 Jan;91(1):42-6 PMID: 11189822
  7. Managing chronic hepatitis C acquired through intravenous drug use.
    QJM. 2001 Mar;94(3):153-8 PMID: 11259690
  8. Treatment of hepatitis C infection in injection drug users.
    Hepatology. 2001 Jul;34(1):188-93 PMID: 11431750
  9. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
    N Engl J Med. 2001 Jul 19;345(3):211-5 PMID: 11463019
  10. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Lancet. 2001 Sep 22;358(9286):958-65 PMID: 11583749
  11. Determinants of viral clearance and persistence during acute hepatitis C virus infection.
    J Exp Med. 2001 Nov 19;194(10):1395-406 PMID: 11714747
  12. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997.
    Am J Public Health. 2002 Nov;92(11):1789-94 PMID: 12406810
  13. Prevention of spread of hepatitis C.
    Hepatology. 2002 Nov;36(5 Suppl 1):S93-8 PMID: 12407581
  14. Prevention and treatment of hepatitis C in injection drug users.
    Hepatology. 2002 Nov;36(5 Suppl 1):S210-9 PMID: 12407596
  15. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.
    J Infect Dis. 2002 Dec 1;186(11):1558-64 PMID: 12447730
  16. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b.
    Clin Ther. 2002 Oct;24(10):1627-35 PMID: 12462291
  17. Case-reporting of acute hepatitis B and C among injection drug users.
    J Urban Health. 2002 Dec;79(4):579-85 PMID: 12468677
  18. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Hepatology. 2003 Feb;37(2):443-51 PMID: 12540795
  19. Treatment of chronic hepatitis C in a state correctional facility.
    Ann Intern Med. 2003 Feb 4;138(3):187-90 PMID: 12558357
  20. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.
    Am J Gastroenterol. 2003 Oct;98(10):2281-8 PMID: 14572580
  21. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46 PMID: 14768714
  22. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
    Hepatology. 2004 Jul;40(1):120-4 PMID: 15239094
  23. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit.
    Gastroenterol Clin Biol. 2004 Jun-Jul;28(6-7 Pt 1):533-9 PMID: 15243385
  24. Correlates of hepatitis C virus infections among injection drug users.
    Medicine (Baltimore). 1995 Jul;74(4):212-20 PMID: 7623656
  25. Management of hepatitis C.
    NIH Consens Statement. 1997 Mar 24-26;15(3):1-41 PMID: 9457159
  26. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S11-9 PMID: 9663618
  27. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.
    MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39 PMID: 9790221
  28. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.
    Hepatology. 1999 Mar;29(3):908-14 PMID: 10051497
  29. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
    N Engl J Med. 1999 Aug 19;341(8):556-62 PMID: 10451460
  30. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study.
    BMJ. 2005 Jan 1;330(7481):24-5 PMID: 15533854
  31. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection.
    Semin Liver Dis. 2005 Feb;25(1):18-32 PMID: 15731995
  32. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.
    Infection. 2005 Feb;33(1):25-9 PMID: 15750756
  33. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S276-85 PMID: 15768335
  34. Treatment for hepatitis C virus infection among current injection drug users in Australia.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9 PMID: 15768342
  35. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S330-5 PMID: 15768343
  36. Follow-up studies of treatment for hepatitis C virus infection among injection drug users.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S336-8 PMID: 15768344
  37. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S339-45 PMID: 15768345
  38. Delivering care to injection drug users coinfected with HIV and hepatitis C virus.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S355-61 PMID: 15768348
  39. Opportunities to address the hepatitis C epidemic in the correctional setting.
    Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S367-72 PMID: 15768350
  40. Treatment of hepatitis C viral infections in substance abusers.
    Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):55-67 PMID: 15832589
  41. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.
    J Subst Abuse Treat. 2005 Oct;29(3):159-65 PMID: 16183464
  42. Ethical issues in the treatment of hepatitis C.
    Clin Gastroenterol Hepatol. 2005 Oct;3(10):937-44 PMID: 16234037
  43. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective.
    Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S73-8 PMID: 16265619
  44. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.
    Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66 PMID: 16394797
  45. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.
    Clin Infect Dis. 2006 Mar 1;42(5):669-72 PMID: 16447112
Article Info
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Abbr.
Clin Infect Dis
ISSN
1537-6591
DOI
10.1086/499960
Published
2006-03-01
Epub
2006-00-20
Pages
673-6
Language
English
Region
United States
NLM ID
9203213
PMCID
PMC1611492
Subset
IM
Grants
NIDA NIH HHS · R01 DA013245 · United States
NCRR NIH HHS · M01 RR000047 · United States
NIDA NIH HHS · R01 DA009532 · United States
NIDA NIH HHS · R01-DA-09532 · United States
NIDA NIH HHS · R01 DA016159 · United States
NIDA NIH HHS · R01-DA-16159 · United States
Corrections
CommentOn
PMID: 16447112
External Links
PubMed source DOI: 10.1086/499960 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2